Skip to main content
Erschienen in: Digestive Diseases and Sciences 5/2022

03.05.2021 | Original Article

A True Positive and a False Negative? The Dilemma of Negative Colonoscopy After a Positive Fecal Occult Blood Test

verfasst von: J. S. Hunt, C. Cock, E. L. Symonds

Erschienen in: Digestive Diseases and Sciences | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Many colonoscopies following a positive fecal immunochemical test (FIT) will not identify a probable cause for fecal blood, and missed neoplasia is a concern. The study determined whether the absence of neoplasia at a FIT positive diagnostic colonoscopy was due to a missed lesion and whether the initial FIT hemoglobin (f-Hb) concentration could predict missed lesions.

Methods

This was a retrospective audit of patients who had undergone diagnostic colonoscopy after FIT screening (2 sample ≥ 20 µg Hb/g feces). Probable bleeding lesions including cancer, advanced adenoma, colitis, and angiodysplasia were considered a “positive colonoscopy outcome.” For those with a negative outcome, findings at the subsequent colonoscopy were assessed.

Results

There were 1087 good quality colonoscopies within 12 months of a positive FIT. In total, 171 (15.7%) patients had a positive outcome at the diagnostic colonoscopy. Subsequent colonoscopies of negative outcome cases (n = 418, median of 3.1y later) were reviewed; of these, there were 57 (13.6%) cases with a positive outcome. This included CRC in 0.5% (n = 2) and advanced adenoma in 11.7% (n = 49). High f-Hb and having both FIT samples ≥ 20 µg/g feces were associated with a positive outcome at the original diagnostic colonoscopy (p < 0.05). However, f-Hb was not predictive for a positive outcome at the subsequent colonoscopy by either maximum f-Hb (p = 0.768), total f-Hb (p = 0.459), or both FIT samples ≥ 20 µg/g (p = 0.091).

Conclusion

A small proportion of “false” positive FIT results had cancer or advanced adenoma found at the subsequent colonoscopy. A missed lesion could not be predicted by the initial FIT f-Hb.
Literatur
5.
6.
Zurück zum Zitat AIHW, Analysis of bowel cancer outcomes for the National Bowel Cancer Screening Program. 2018: Australian Institute of Health and Welfare Canberra. AIHW, Analysis of bowel cancer outcomes for the National Bowel Cancer Screening Program. 2018: Australian Institute of Health and Welfare Canberra.
8.
Zurück zum Zitat Cole SR, Tucker GR, Osborne JM et al. Shift to earlier stage at diagnosis as a consequence of the National Bowel Cancer Screening Program. Med J Aust. 2013;198:327–330.CrossRef Cole SR, Tucker GR, Osborne JM et al. Shift to earlier stage at diagnosis as a consequence of the National Bowel Cancer Screening Program. Med J Aust. 2013;198:327–330.CrossRef
18.
Zurück zum Zitat Bampton PA, Sandford JJ, Young GP. Applying evidence-based guidelines improves use of colonoscopy resources in patients with a moderate risk of colorectal neoplasia. Med J Aust. 2002;176:155–157.CrossRef Bampton PA, Sandford JJ, Young GP. Applying evidence-based guidelines improves use of colonoscopy resources in patients with a moderate risk of colorectal neoplasia. Med J Aust. 2002;176:155–157.CrossRef
20.
Zurück zum Zitat Fenocchi E, Gaggero P, Rondán M et al. Usefulness of the fecal immunochemical test in the detection of advanced adenomas in subjects at average risk for colorectal cancer. Endoscopia. 2015;27:64–68.CrossRef Fenocchi E, Gaggero P, Rondán M et al. Usefulness of the fecal immunochemical test in the detection of advanced adenomas in subjects at average risk for colorectal cancer. Endoscopia. 2015;27:64–68.CrossRef
21.
Zurück zum Zitat Australian Bureau of Statistic. Socio-economic Indexes for Areas: Technical Paper, 2016. 2016; cat. no. 2033.0.55.001:[ Australian Bureau of Statistic. Socio-economic Indexes for Areas: Technical Paper, 2016. 2016; cat. no. 2033.0.55.001:[
Metadaten
Titel
A True Positive and a False Negative? The Dilemma of Negative Colonoscopy After a Positive Fecal Occult Blood Test
verfasst von
J. S. Hunt
C. Cock
E. L. Symonds
Publikationsdatum
03.05.2021
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 5/2022
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-06986-4

Weitere Artikel der Ausgabe 5/2022

Digestive Diseases and Sciences 5/2022 Zur Ausgabe

DDS–SIRC COOPERATIVE CONFERENCES

Duodenal Follicular Lymphoma: Track or Treat?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.